ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that Dr. Claire Verschraegen of the University of New Mexico, Albuquerque, lead author of the abstract on the palifosfamide study entitled, "A phase II randomized controlled trial of palifosfamide plus doxorubicin vs. doxorubicin in patients with soft tissue sarcoma (PICASSO)", will present in an oral session at the American Society of Clinical Oncology (ASCO) Annual Meeting on Monday, June 7th at 2:15 pm in the Vista Room (location S 406). The abstract has been selected as part of the 2010 Best of ASCO® educational program. Best of ASCO® sessions will be held in both San Francisco and Boston in the United States and in several countries around the world in the months following the ASCO Annual Meeting. Best of ASCO® features high-impact abstracts from the ASCO Annual Meeting that represent the most relevant, cutting-edge science in oncology today.
“A phase II randomized controlled trial of palifosfamide plus doxorubicin vs. doxorubicin in patients with soft tissue sarcoma (PICASSO)”
The abstract (# 10004) released on the www.ASCO.org website states, "A total of sixty-seven patients with STS were randomized with 66 treated and 62 eligible. Enrollment was stopped early because of positive efficacy. Sixty-two patients were evaluated for progression-free survival (PFS) with 28 documented PFS events (doxorubicin alone = 18 events; palifosfamide + doxorubicin = 10 events). With this interim analysis of all randomized and eligible patients, the hazard ratio is 0.43 favoring palifosfamide + doxorubicin (two-sided Wilcoxon-Gehan p-value = 0.019). The median PFS was 4.4 months for doxorubicin and 7.8 months for palifosfamide + doxorubicin. No significant difference in toxicities between the arms was noted, and the combination of palifosfamide + doxorubicin has been well tolerated as an outpatient treatment."
AI chatbot offers accurate answers to radiation oncology queries